Compare STRA & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRA | GLUE |
|---|---|---|
| Founded | 2017 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1996 | 2021 |
| Metric | STRA | GLUE |
|---|---|---|
| Price | $75.33 | $18.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $87.00 | $32.00 |
| AVG Volume (30 Days) | 203.1K | ★ 904.2K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.04% | N/A |
| EPS Growth | ★ 15.85 | N/A |
| EPS | ★ 1.48 | N/A |
| Revenue | ★ $997,137,000.00 | $123,672,000.00 |
| Revenue This Year | $4.71 | N/A |
| Revenue Next Year | $4.67 | $2.45 |
| P/E Ratio | ★ $50.49 | $72.42 |
| Revenue Growth | 57.23 | ★ 63.54 |
| 52 Week Low | $69.70 | $4.12 |
| 52 Week High | $88.50 | $25.77 |
| Indicator | STRA | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 51.65 |
| Support Level | $75.10 | $17.07 |
| Resistance Level | $83.97 | $18.66 |
| Average True Range (ATR) | 2.20 | 1.20 |
| MACD | -0.54 | 0.10 |
| Stochastic Oscillator | 23.42 | 58.67 |
Strategic Education Inc. is an education services company that provides access to high-quality education through campus-based and online post-secondary education offerings, as well as through programs to develop job-ready skills for high-demand markets. The company operates through wholly-owned subsidiaries Strayer University and Capella University, both accredited post-secondary institutions of higher education located in the United States, as well as Torrens University, an accredited post-secondary institution of higher education located in Australia. It provide employees with access to affordable and industry relevant training, certificate, and degree programs. The reportable segments of the company are U.S. Higher Education, Australia/New Zealand and Education Technology Services.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).